ResMed buys HST company

SAN DIEGO – ResMed has bought Ectosense, which makes the NightOwl home sleep test. 

The NightOwl, approved by the U.S. Food and Drug Administration, is currently sold in the United States, Australia, New Zealand, India and parts of Europe. ResMed has distributed the NightOwl, under the brand ResMed onesleeptest, in Australia, New Zealand and India since 2020, and has been a minority investor in Ectosense since July 2020. 

"Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea," said Jim Hollingshead, ResMed president of sleep and respiratory care. "We believe Ectosense's digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. For millions of people, their best night's sleep must start with a diagnosis." 

Terms of the transaction, which will not be material to ResMed’s consolidated financial results, were not disclosed. 

Ecotosense will operate within ResMed’s sleep and respiratory care business. 

"ResMed has the global reach and passionate ambition to help increase patient access to Ectosense's proven diagnostic solution and a path to better sleep and overall health," said Frederik Massie, CTO and co-founder of Ectosense. "It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don't even know it."